New drug aims to tame immunotherapy side effects in cancer patients
NCT ID NCT07313202
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This study looks at whether Ivarmacitinib can help manage severe immune-related side effects in people with advanced solid tumors who had to stop immunotherapy. It involves 72 participants split into two groups based on how their side effects respond to steroids. The goal is to control these reactions and possibly allow patients to restart cancer treatment safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED SOLID TUMORS WHO DISCONTINUED TREATMENT DUE TO IRAE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.